1. Home
  2. CHRS vs VBF Comparison

CHRS vs VBF Comparison

Compare CHRS & VBF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CHRS
  • VBF
  • Stock Information
  • Founded
  • CHRS 2010
  • VBF 1970
  • Country
  • CHRS United States
  • VBF United States
  • Employees
  • CHRS 235
  • VBF N/A
  • Industry
  • CHRS Biotechnology: Biological Products (No Diagnostic Substances)
  • VBF Trusts Except Educational Religious and Charitable
  • Sector
  • CHRS Health Care
  • VBF Finance
  • Exchange
  • CHRS Nasdaq
  • VBF Nasdaq
  • Market Cap
  • CHRS 134.4M
  • VBF 177.3M
  • IPO Year
  • CHRS 2014
  • VBF N/A
  • Fundamental
  • Price
  • CHRS $1.21
  • VBF $15.82
  • Analyst Decision
  • CHRS Strong Buy
  • VBF
  • Analyst Count
  • CHRS 4
  • VBF 0
  • Target Price
  • CHRS $5.38
  • VBF N/A
  • AVG Volume (30 Days)
  • CHRS 2.4M
  • VBF 45.5K
  • Earning Date
  • CHRS 03-12-2025
  • VBF 01-01-0001
  • Dividend Yield
  • CHRS N/A
  • VBF 5.18%
  • EPS Growth
  • CHRS N/A
  • VBF N/A
  • EPS
  • CHRS N/A
  • VBF N/A
  • Revenue
  • CHRS $304,340,000.00
  • VBF N/A
  • Revenue This Year
  • CHRS $2.47
  • VBF N/A
  • Revenue Next Year
  • CHRS N/A
  • VBF N/A
  • P/E Ratio
  • CHRS N/A
  • VBF N/A
  • Revenue Growth
  • CHRS 44.19
  • VBF N/A
  • 52 Week Low
  • CHRS $0.66
  • VBF $13.68
  • 52 Week High
  • CHRS $2.87
  • VBF $16.27
  • Technical
  • Relative Strength Index (RSI)
  • CHRS 44.03
  • VBF 56.46
  • Support Level
  • CHRS $1.03
  • VBF $15.67
  • Resistance Level
  • CHRS $1.23
  • VBF $16.09
  • Average True Range (ATR)
  • CHRS 0.13
  • VBF 0.19
  • MACD
  • CHRS -0.02
  • VBF 0.04
  • Stochastic Oscillator
  • CHRS 38.89
  • VBF 58.46

About CHRS Coherus BioSciences Inc.

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. The company is focused on the research, development, and commercialization of its portfolio of FDA-approved oncology products, including LOQTORZI. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company generates revenue from the United States.

About VBF Invesco Bond Fund

Invesco Bond Fund is an independent investment management firm. Its investment objective is to seek interest income while conserving capital.

Share on Social Networks: